Sonexa Therapeutics
Drug treatments for alzheimer's disease and related disorders
About Sonexa Therapeutics
Sonexa Therapeutics, Inc. is a clinical-stage biopharmaceutical company established in 2007 with a focus on developing treatments for Alzheimer's disease. The company was founded by Eckard Weber, M.D., who served as the founding CEO and Chairman. Dr. Weber, a partner at Domain Associates, has a significant track record, having been the founding CEO for over a dozen biopharmaceutical companies, including Cerexa, which was acquired by Forest Laboratories. The management team also included President and CMO Sharon Rogers, Ph.D., who had a key role in the development of Aricept, a leading Alzheimer's medication.
The company's business model is centered on identifying and in-licensing promising drug candidates to develop them through clinical trials. Sonexa secured a significant $30 million in a Series A financing round in January 2008, led by Domain Associates, Scale Venture Partners, and Alta Partners, with additional investors including AgeChem Venture Fund and MC Life Science Ventures. This initial funding was intended to support the development of a novel drug for Alzheimer's, for which Sonexa licensed exclusive worldwide rights (excluding Japan and certain Asian countries) from a Japanese pharmaceutical company. Over its lifetime, the company has raised a total of $71.5 million across five funding rounds.
Sonexa's primary product candidate is ST101, a small, orally active molecule designed to penetrate the blood-brain barrier. The company has conducted several Phase 2 clinical trials to evaluate the efficacy, safety, and tolerability of ST101 in treating Alzheimer's disease, both as a standalone treatment and in conjunction with existing medications like donepezil (Aricept). Another Phase 2 study explored ST101's potential for treating Essential Tremor. The company operates on a semi-virtual model, outsourcing many functions to a team of full and part-time staff to maintain operational flexibility during the start-up and clinical development phases.
Source: Dealroom company dataAt a glance
- Founded
- 2007
- Headquarters
- San Diego, United States
- Sector
- Biotech & Life Sciences
News
Open roles
Sonexa Therapeutics in the San Diego ecosystem
The Sonexa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Alta Partners
Scale Venture Partners
Domain Associates
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sonexa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sonexa Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

